Since 2014, the health care industry mergers and acquisitions investment activity has attracted the attention of fund companies. Recently, a number of medical and medical listed companies announced that ICBC Credit Suisse, Baoying Fund, Rongtong Fund, Cinda Aussie and other fund companies have gathered together to research Laimei Pharmaceutical, Changhong Technology and Yangpu Medical. The Securities Times reporter noted that in the contents of the investor relations activities disclosed by the above companies, investors have inquired about the company's merger and acquisition plan.
ICBC Credit Suisse, Baoying Fund and Changsheng Fund investigated Chongqing Laimei Pharmaceutical on June 23. Just two days before the agency's investigation, Chongqing Laimei Pharmaceutical announced that it would terminate the resumption of major events. In the research activities, investors asked about the reasons for the termination of major events and the follow-up plan. Laimei said that the main reason for the failure of the major transaction was that the parties did not reach an agreement on the specific transaction content and methods, and the subsequent Laimei Pharmaceuticals will Continue to strengthen mergers and acquisitions, the standard is still in the field of medicine, focusing on whether the target of the acquisition has a fist product and whether it has sustained performance growth.
Changhong Technology, which specializes in medical injection molding, has attracted six fund companies to conduct research. On June 19th, Donghai Fund, Rongtong Fund, Cinda Aussie, SDIC UBS Fund, Penghua Fund, Baoying Fund and other fund companies gathered in Changhong Technology. In the communication session, investors are most concerned about Changhong Technology. The disclosures disclosed in the 2013 Annual Report will quickly cut into high-growth medical device segments through mergers and acquisitions. Changhong Technology said that the fields of rapid development of the medical industry include medical informatization , in vitro diagnostic reagents and high-end medical consumables. Changhong Technology will develop medical projects based on internal and outreaching strategies.
In addition, Yangpu Medical, which has recently been active in mergers and acquisitions, is also welcoming the investigation of the Bank of China Fund. Yangpu Medical said that the current company merger is mainly responsible for the holding subsidiary Yanghe Investment, has acquired three related industry companies, including investment in Guangzhou Weisoft Information Technology Co., Ltd. (image), Beijing Kushur Medical Technology Co., Ltd. (None Needle syringe) and Xiamen Channel Biotechnology Co., Ltd. (fecal detection).
Since 2014, the pace of M&A in the healthcare industry has accelerated. According to financial terminal software statistics, since 2014, as of June 25, A-share companies have disclosed a total of 158 M&A investment transactions with medical and pharmaceutical products as the target. Among them, 83 completed M&A transactions, the total transaction amount is 10.7 billion yuan, an increase of 245% and 7% respectively over the same period last year. In addition, in the first half of this year, there were 69 transactions that were not completed, involving an amount of approximately RMB 16.8 billion.
Zhoushan City Shuangying Aquatic Products Co., Ltd.  , https://www.shuangying-aquatic.com